Phil has 19+ years of experience auditing the financial statement close processes of several large, multinational life sciences companies. Significant experience advising life sciences clients on deal structures outlining the accounting considerations of M&A, license, and option deals before such deals are entered into

Phil led the IPO process for 7 life sciences companies over the last 5 years, incl. assisting with SEC filing requirements and documents, pro forma financial statements, and US GAAS/PCAOB uplift procedures. Lead the first year SOX implementation process for a $8.0 billion market cap. life sciences company. Significant experience serving pre-IPO life sciences clients

Phil has experience advising clients on new accounting standards as well as designing and harmonizing accounting policies/manuals. Working on capital market transactions, incl. financial due diligence and assurance on filing documents.

Phil was project lead for the US West Life Sciences ASC 606 revenue taskforce and the development and certification of EY Assurance’s Life Sciences Gross-to-Net Revenue Analyzer data analytics tool.

2 years as the Assurance Resident in Ernst & Young’s Global Life Science Center in Boston where he consulted with clients and engagement teams on auditing and reporting issues that impact life science companies and developed thought leadership for Ernst & Young’s Global Life Sciences practice.

Selection of life sciences clients served: Insitro, Freenome Holdings, Neumora Therapeutics, Maravai LifeSciences Holdings, Rani Therapeutics Holdings, Talis Biomedical, Portola Pharmaceuticals, Zogenix, Gilead Sciences, Gritstone Oncology, Guardant Health, Unity Biotechnology, Assembly Biosciences, CymaBay Therapeutics, Ocera Therapeutics, Ventana Medical Systems (now a division of Roche diagnostics), HTG Molecular Diagnostics, Immunodiagnostic Systems, W.L. Gore & Associates (medical products division).